Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Hong Laura Lu"'
Publikováno v:
Model Assisted Statistics and Applications. 5:151-157
Publikováno v:
Journal of Clinical Oncology. 27:2874-2880
Several challenging and often controversial issues arise in oncology trials with the use of the end point progression-free survival (PFS), defined to be the time to detection of progressive disease or death. While this end point does not directly mea
Autor:
Hong Laura Lu, Mohammad F. Huque
Publikováno v:
Biometrical Journal. 43:909-923
Several independent clinical trials are usually conducted to demonstrate and support the evidence of the efficacy of a new drug. When not all the trials demonstrate a treatment effect because of a lack of statistical significant finding, the sponsor
Autor:
Kallappa Koti, Hong Laura Lu, Haojin Zhou, Yuan Li Shen, Mei Jin, Jenny J. Zhang, Mark Rothmann, Kyung Yul Lee
Publikováno v:
Journal of biopharmaceutical statistics. 23(5)
The intent-to-treat principle, grouping subjects as they were randomized and following all subjects to the endpoint or the end of study, allows valid statistical comparisons. Progression-free survival (PFS) has been used as a decision-making endpoint
Publikováno v:
Journal of biopharmaceutical statistics. 19(6)
The intent-to-treat principle requires analyses according to the treatment groups to which patients were randomized and that patients be followed to the occurrence of the endpoint or the end of study. This provides unbiased comparisons with valid p v
Publikováno v:
Model Assisted Statistics & Applications; 2010, Vol. 5 Issue 3, p151-157, 7p, 6 Charts